Immunotherapy of reactivated cytomegalovirus (CMV) infection in immunocompromised HCT recipients by adoptive transfer (AT) of antiviral CD8 T cells is the last resort to fight virus variants that have acquired resistance to standard antiviral drugs. The gene discussed is CD8A; the disease is cytomegalovirus infection.